{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T11:26:23Z","timestamp":1786965983431,"version":"build-2736575974"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>A reduction in loop diuretics need after sodium\u2013glucose cotransporter-2 inhibitors (SGLT2i) initiation has been suggested by retrospective analyses of clinical trials. We aimed to investigate long-term changes in loop diuretic therapy after SGLT2i initiation in an unselected, real-world heart failure (HF) cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Patients with HF with reduced ejection fraction (HFrEF) enrolled in the SwedeHF between January 2020 and October 2021 were considered. Patients initiated with SGLT2i were the cases. Controls did not initiate SGLT2i despite having an indication. Trajectories in daily furosemide-equivalent doses from baseline to 1-year follow-up were compared in cases vs. controls. Overall, 5623 (81.6%) controls and 1265 (18.4%) cases were analysed. At baseline, 5224 (75.8%) patients were prescribed with loop diuretics with a mean (SD) furosemide-equivalent dose of 36.7 (27.4) mg. SGLT2i users, compared with controls, more likely experienced a loop diuretic withdrawal\/dose reduction (difference between proportions 6% [3%; 9%] P-value &amp;lt;0.001), and less likely had a loop diuretic initiation or dose increase (difference between proportions \u22125% [\u22127%; \u22123%], P-value &amp;lt;0.001), leading to a more accentuated net decrease in furosemide-equivalent daily doses (adjusted mean difference between groups \u22124.2 [\u22127; \u22121.5] mg, P-value 0.002). In a multivariable regression model, the adjusted odds ratio (OR) for decrease in loop diuretic doses\/withdrawn after SGLT2i initiation was 1.58 (1.35\u20131.85), and the adjusted OR for increase in loop diuretic doses\/new initiation was 0.50 (0.38\u20130.64).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this real-world population with HFrEF, SGLT2i initiation was associated with a decrease in loop diuretic need at 1-year follow-up.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvag041","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T11:28:54Z","timestamp":1781004534000},"page":"379-389","source":"Crossref","is-referenced-by-count":1,"title":["Longitudinal loop diuretic use in patients with HFrEF initiated with sodium\u2013glucose cotransporter 2 inhibitors"],"prefix":"10.1093","volume":"12","author":[{"given":"Daniela","family":"Tomasoni","sequence":"first","affiliation":[{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset, Karolinska Institutet , Sjukhusbacken 10, Stockholm 118 83 ,","place":["Sweden"]},{"name":"Cardiology\u2013ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia , 25123 Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5393-0055","authenticated-orcid":false,"given":"Lina","family":"Benson","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset, Karolinska Institutet , Sjukhusbacken 10, Stockholm 118 83 ,","place":["Sweden"]},{"name":"Department of Medicine, Division of Cardiology , Karolinska Institutet, SE-171 76 Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7683-4720","authenticated-orcid":false,"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Baylor Scott and White Research Institute , 3434 Live Oak St Ste 501, Dallas, TX 75204 ,","place":["USA"]},{"name":"University of Mississippi Department of Medicine, \u00a0 2500 N State St, Jackson, MS 39216 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Guidetti","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset, Karolinska Institutet , Sjukhusbacken 10, Stockholm 118 83 ,","place":["Sweden"]},{"name":"Department of Cardiology, University Cardiovascular Centre, Bern University Hospital, Inselspital , 3010 Bern ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Melin","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset, Karolinska Institutet , Sjukhusbacken 10, Stockholm 118 83 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carin","family":"Corovic Cabrera","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset, Karolinska Institutet , Sjukhusbacken 10, Stockholm 118 83 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Metra","sequence":"additional","affiliation":[{"name":"Cardiology\u2013ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia , 25123 Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars H","family":"Lund","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology , Karolinska Institutet, SE-171 76 Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7732-0887","authenticated-orcid":false,"given":"Gianluigi","family":"Savarese","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset, Karolinska Institutet , Sjukhusbacken 10, Stockholm 118 83 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"2026081706514954100_pvag041-B1","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"2026081706514954100_pvag041-B2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/ehjcvp\/pvad088","article-title":"Sodium glucose co-transporter 2 inhibitors and quality of life in patients with heart failure: a comprehensive systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Oriecuia","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026081706514954100_pvag041-B3","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/ejhf.2397","article-title":"Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction","volume":"24","author":"Tomasoni","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026081706514954100_pvag041-B4","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1002\/ehf2.15408","article-title":"SGLT2 inhibitors for the prevention and treatment of heart failure: a scientific statement of the HFA and the HFAI","volume":"12","author":"Metra","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026081706514954100_pvag041-B5","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.123.064346","article-title":"Critical analysis of the effects of SGLT2 inhibitors on renal tubular sodium, water and chloride homeostasis and their role in influencing heart failure outcomes","volume":"148","author":"Packer","year":"2023","journal-title":"Circulation"},{"key":"2026081706514954100_pvag041-B6","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jacc.2024.02.020","article-title":"Water conservation overrides osmotic diuresis during SGLT2 inhibition in patients with heart failure","volume":"83","author":"Marton","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026081706514954100_pvag041-B7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jchf.2023.06.036","article-title":"Efficacy and safety of empagliflozin according to background diuretic use in HFrEF: post-hoc analysis of EMPEROR-reduced","volume":"12","author":"Dhingra","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2026081706514954100_pvag041-B8","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1161\/CIRCULATIONAHA.120.047077","article-title":"Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF","volume":"142","author":"Jackson","year":"2020","journal-title":"Circulation"},{"key":"2026081706514954100_pvag041-B9","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1001\/jamacardio.2023.1090","article-title":"Safety and efficacy of empagliflozin and diuretic use in patients with heart failure and preserved ejection fraction: a post hoc analysis of the EMPEROR-preserved trial","volume":"8","author":"Butler","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2026081706514954100_pvag041-B10","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1093\/eurheartj\/ehad283","article-title":"Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial","volume":"44","author":"Chatur","year":"2023","journal-title":"Eur Heart J"},{"key":"2026081706514954100_pvag041-B11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/03009734.2018.1490831","article-title":"The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure","volume":"124","author":"Savarese","year":"2019","journal-title":"Ups J Med Sci"},{"key":"2026081706514954100_pvag041-B12"},{"key":"2026081706514954100_pvag041-B13","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","article-title":"Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC heart failure long-term registry","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026081706514954100_pvag041-B14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jchf.2018.10.010","article-title":"Contemporary drug treatment of chronic heart failure with reduced ejection fraction: the CHECK-HF registry","volume":"7","author":"Brunner-La Rocca","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026081706514954100_pvag041-B15","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.008351","article-title":"Diuretic changes, health care resource utilization, and clinical outcomes for heart failure with reduced ejection fraction: from the change the management of patients with heart failure registry","volume":"14","author":"Khan","year":"2021","journal-title":"Circ Heart Fail"},{"key":"2026081706514954100_pvag041-B16","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/ejhf.1796","article-title":"Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP heart failure long-term registry","volume":"22","author":"Kapelios","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026081706514954100_pvag041-B17","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1002\/ejhf.3295","article-title":"How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the Heart Failure Association of the ESC","volume":"26","author":"Savarese","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026081706514954100_pvag041-B18","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jacc.2024.04.055","article-title":"Effects of rapid uptitration of neurohormonal blockade on effective, sustainable decongestion and outcomes in STRONG-HF","volume":"84","author":"Biegus","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026081706514954100_pvag041-B19","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehag199","article-title":"Heart failure with reduced ejection fraction in Sweden: patient adherence and persistence to quadruple pharmacotherapy prescription","author":"Lindberg","journal-title":"Eur Heart J"},{"key":"2026081706514954100_pvag041-B20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jchf.2023.09.013","article-title":"SGLT2 inhibitors and diuresis: a small piece of the puzzle","volume":"12","author":"Vardeny","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2026081706514954100_pvag041-B21","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","article-title":"Empagliflozin in heart failure: diuretic and cardiorenal effects","volume":"142","author":"Griffin","year":"2020","journal-title":"Circulation"},{"key":"2026081706514954100_pvag041-B22","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/ejhf.2874","article-title":"Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology","volume":"25","author":"Metra","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026081706514954100_pvag041-B23","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1161\/CIRCULATIONAHA.120.047480","article-title":"Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction: a prespecified analysis of DAPA-HF","volume":"142","author":"Docherty","year":"2020","journal-title":"Circulation"},{"key":"2026081706514954100_pvag041-B24","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/ejhf.762","article-title":"Association between enrolment in a heart failure quality registry and subsequent mortality-a nationwide cohort study","volume":"19","author":"Lund","year":"2017","journal-title":"Eur J Heart Fail"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvag041\/68506145\/pvag041.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/12\/5\/379\/68506145\/pvag041.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/12\/5\/379\/68506145\/pvag041.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T10:51:57Z","timestamp":1786963917000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/12\/5\/379\/8705312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":24,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,6,10]]},"published-print":{"date-parts":[[2026,8,17]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvag041","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,6,10]]}}}